Organovo Holdings Inc (ONVO)
1.165
+0.04
(+4.02%)
USD |
NASDAQ |
Apr 18, 16:00
1.20
+0.04
(+3.00%)
After-Hours: 20:00
Organovo Holdings Revenue (Quarterly): 0.005M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.005M |
| September 30, 2023 | |
| June 30, 2023 | 0.075M |
| March 31, 2023 | 0.162M |
| December 31, 2022 | 0.131M |
| September 30, 2022 | 0.077M |
| June 30, 2022 | |
| March 31, 2022 | 1.50M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.298M |
| September 30, 2019 | 1.23M |
| June 30, 2019 | 0.668M |
| March 31, 2019 | 0.68M |
| December 31, 2018 | 0.779M |
| September 30, 2018 | 0.943M |
| June 30, 2018 | 0.689M |
| March 31, 2018 | 1.105M |
| December 31, 2017 | 1.153M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.355M |
| June 30, 2017 | 0.99M |
| March 31, 2017 | 0.812M |
| December 31, 2016 | 1.151M |
| September 30, 2016 | 1.376M |
| June 30, 2016 | 0.891M |
| March 31, 2016 | 0.548M |
| December 31, 2015 | 0.328M |
| September 30, 2015 | 0.301M |
| June 30, 2015 | 0.306M |
| March 31, 2015 | 0.267M |
| December 31, 2014 | 0.155M |
| September 30, 2014 | 0.05M |
| June 30, 2014 | 0.099M |
| March 31, 2014 | 0.115M |
| December 31, 2013 | 0.135M |
| September 30, 2013 | 0.023M |
| June 30, 2013 | 0.106M |
| December 31, 2012 | 0.3488M |
| September 30, 2012 | 0.4692M |
| June 30, 2012 | 0.259M |
| March 31, 2012 | 0.12M |
| December 31, 2011 | |
| September 30, 2011 | 0.0017M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.005M
Minimum
Dec 2023
1.50M
Maximum
Mar 2022
0.4607M
Average
0.162M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.065M |
| IGC Pharma Inc | 0.204M |
| NovaBay Pharmaceuticals Inc | 3.727M |
| Protalix BioTherapeutics Inc | 10.49M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.604M |
| Total Expenses (Quarterly) | 3.685M |
| EPS Diluted (Quarterly) | -0.40 |
| Enterprise Value | 6.452M |
| Profit Margin (Quarterly) | -72.08K% |
| Earnings Yield | -180.8% |
| Normalized Earnings Yield | -182.29 |